Abstract library

1 results for "Tremelimumab".
#2068 Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) of Lung or Gastroenteropancreatic (GEP) Origin. A Phase II Multicohort Trial (DUNE Trial / GETNE 1601)
Introduction: Immuno check-point inhibitors development in grade 1-2 NENs is limited by low mutation tumor load and PD-1/PDL-1 expression. The combination of an PDL-1 and CTLA-4 inhibitors could increase the probability of success in this setting. In high grade NENs the rational for immunotherapy is stronger based on experiences in small cell lung cancer.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - others, not specified
Presenting Author: MD PhD Jorge Hernando-Cubero